Science and Technology

AndroScience Corporation’s (ASC) research and drug discovery strategy utilizes novel small molecule approaches to selectively block disease causing intracellular signaling pathways. ASC pharmaceutical pipeline is supported by two distinct therapeutic drug platforms, each consisting of select lead products derived from a larger portfolio of compounds which provide second generation candidates continually under optimization. Each of ASC’s core platforms possess medicinal and administration route properties which allow for pursuing several distinct clinical indications in parallel.

The first of ASC’s drug discovery programs utilizes a targeted approach to treat androgen related diseases through interrupting androgen signaling via enhancing androgen receptor (AR) protein degradation, i.e., removing receptors. The second source of pipeline drugs is based on inhibiting specific Signal Transducer and Activator of Transcription (STAT) proteins, a family of intracellular transcription factors involved in cancer transformation.


COS1         COS2

Home | Corporate Overview | Product Pipeline | Science & Technology | News & Events | Contact Us | Privacy Policy